» Articles » PMID: 30814839

Breast Cancer in Very Young Patients in a Spanish Cohort: Age As an Independent Bad Prognostic Indicator

Overview
Publisher Sage Publications
Date 2019 Mar 1
PMID 30814839
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Breast cancer (BC) in very young women (BCVY) is more aggressive than in older women. The purpose of this study was to evaluate the relevance of a range of clinico-pathological factors in the prognosis of BCVY patients.

Methods: We retrospectively analyzed 258 patients diagnosed with BCVY at our hospital from 1998 to 2014; the control group comprised 101 older patients with BC. We correlated clinicopathological factors, treatments, relapse and exitus with age and with previously published miRNA expression data.

Results: We identified some significant differences in risk factors between BCVY and older patients. The age at menarche, number of pregnancies, and age at first pregnancy were lower in the BCVY group and had a greater probability of recurrence and death in all cases. Lymph node-positive patients in the BCVY group are associated with a worse prognosis (  .02), an immunohistochemical HER2 subtype, and disease relapse (  .03). Moreover, there was a shorter time between diagnosis and first relapse in BCVY patients compared with controls, and they were more likely to die from the disease (  .002). Finally, from our panel of miRNAs deregulated in BC, reduced miR-30c expression was associated with more aggressive BC in very young patients, lower overall survival, and with axillary lymph node metastases.

Conclusions: Patient age and axillary lymph node status post-surgery are independent and significant predictors of distant disease-free survival, local recurrence-free survival, and overall survival. The HER2 subtype and lower miR-30c expression are related to poor prognosis in lymph node-positive young BC patients.

Citing Articles

Association of socioeconomic status with the clinical management and outcomes in young patients (≤35 years) diagnosed with breast cancer: A retrospective analysis.

Birnbaum Z, Jones G, Diaz G, Duncan T, Romero J, Steen S Ann Med Surg (Lond). 2022; 82:104524.

PMID: 36268314 PMC: 9577443. DOI: 10.1016/j.amsu.2022.104524.


Age at initial diagnosis and prognosis of breast cancer: a nationwide multicenter retrospective study in China.

Yang H, Ouyang Q, Yan M, Wang X, Hu X, Jiang Z Ann Transl Med. 2022; 10(15):813.

PMID: 36034985 PMC: 9403943. DOI: 10.21037/atm-22-302.


The Chaperone System in Breast Cancer: Roles and Therapeutic Prospects of the Molecular Chaperones Hsp27, Hsp60, Hsp70, and Hsp90.

Alberti G, Vergilio G, Paladino L, Barone R, Cappello F, de Macario E Int J Mol Sci. 2022; 23(14).

PMID: 35887137 PMC: 9324353. DOI: 10.3390/ijms23147792.


The impact of young age (< 40 years) on the outcome of a cohort of patients with primary non-metastatic breast cancer: analysis of 10-year survival of a prospective study.

Bouferraa Y, Haibe Y, Chedid A, Jabra E, Charafeddine M, Temraz S BMC Cancer. 2022; 22(1):27.

PMID: 34980002 PMC: 8722326. DOI: 10.1186/s12885-021-09100-z.


Specific Roles of HSP27 S15 Phosphorylation Augmenting the Nuclear Function of HER2 to Promote Trastuzumab Resistance.

Hwang S, Choi S, Seo S, Jo H, Shin J, Na Y Cancers (Basel). 2020; 12(6).

PMID: 32545363 PMC: 7352409. DOI: 10.3390/cancers12061540.


References
1.
. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1999; 350(9084):1047-59. View

2.
. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001; 358(9291):1389-99. DOI: 10.1016/S0140-6736(01)06524-2. View

3.
Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B . Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2002; (30):96-102. DOI: 10.1093/oxfordjournals.jncimonographs.a003469. View

4.
Colleoni M, Rotmensz N, Robertson C, Orlando L, Viale G, Renne G . Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol. 2002; 13(2):273-9. DOI: 10.1093/annonc/mdf039. View

5.
Dubsky P, Gnant M, Taucher S, Roka S, Kandioler D, Agstner I . Young age as an independent adverse prognostic factor in premenopausal patients with breast cancer. Clin Breast Cancer. 2002; 3(1):65-72. DOI: 10.3816/CBC.2002.n.013. View